Dalteparin Injection, 2500 IU/0.2 ML, 5000 IU/0.2 ML, 7500 IU/0.3 ML
Dalteparin Injection, 2500 IU/0.2 ML, 5000 IU/0.2 ML, 7500 IU/0.3 ML - Image 2
Dalteparin Injection, 2500 IU/0.2 ML, 5000 IU/0.2 ML, 7500 IU/0.3 ML - Image 3
Categories:, SKU: 00011-142
Dalteparin Injection, 2500 IU/0.2 ML, 5000 IU/0.2 ML, 7500 IU/0.3 ML

Download as PDF
Enquire Now

Description

PRODUCT DESCRIPTION:

 

Dalteparin is a low molecular weight heparin (LMWH) used to prevent and treat blood clots in high-risk patients.

It offers targeted antithrombotic activity with reduced risk of bleeding complications compared to unfractionated heparin. Supplied in sterile, single-use pre-filled syringes, Dalteparin ensures precise dosing, subcutaneous administration convenience, and improved patient compliance.

It is widely used for deep vein thrombosis (DVT) prophylaxis, venous thromboembolism (VTE) prevention in surgical and medical patients, and management of unstable angina or non-Q wave myocardial infarction.

Formulation & Presentation:

  • Dosage Form: Sterile Injectable (Sterile Lyophilized Solution for Reconstitution)
  • Presentation: Pre-Filled Syringe (customizable as per market demand)
  • Available Strengths:
    • 2500 IU/ 0.2 ML (Pre-Filled Syringe)
    • 5000 IU/ 0.2 ML (Pre-Filled Syringe)
    • 7500 IU/ 0.3 ML (Pre-Filled Syringe)
  • Route of Administration: Subcutaneous (SC)/ Intravenous (IV) only in advanced clinical settings, as per clinical indication and severity. To be administered under supervision of a qualified specialist only. (As per physician’s discretion or decision)

Therapeutic Indications:

  • Prophylaxis of deep vein thrombosis (DVT) in surgical and immobilized medical patients
  • Treatment of acute deep vein thrombosis and pulmonary embolism
  • Prevention of clotting in extracorporeal circulation during hemodialysis
  • Management of unstable angina and non-Q-wave myocardial infarction
  • Extended treatment of symptomatic venous thromboembolism in cancer patients

Side Effects:

  • COMMON:
    • Mild injection site irritation or bruising
    • Bleeding tendencies (especially in overdose or high-risk individuals)
    • Mild thrombocytopenia
  • SERIOUS (RARE):
    • Heparin-induced thrombocytopenia (HIT)
    • Severe bleeding or hemorrhagic events
    • Osteoporosis (with long-term use)
    • Hypersensitivity or anaphylactic reactions
  • PRECAUTIONS:
    • Monitor platelet counts regularly to rule out HIT
    • Use with caution in renal impairment, uncontrolled hypertension, or bleeding disorders
    • Not to be mixed with other injections in the same syringe
    • Use under medical supervision with appropriate coagulation monitoring
    • Contraindicated in active major bleeding, recent hemorrhagic stroke, or hypersensitivity to heparins

Reviews

There are no reviews yet.

Be the first to review “Dalteparin Injection, 2500 IU/0.2 ML, 5000 IU/0.2 ML, 7500 IU/0.3 ML”

Your email address will not be published. Required fields are marked *

12345

TECHNICAL INFORMATION

Product Specifications:

  • HSN Code: To be assigned per international classification standards & import jurisdiction
  • Weight: Approx. 40g per Carton (With Packaging)
  • Dimensions: (15x1x8 CMS)
  • Shelf Life (Subject To Country Specific Guidelines): 24 to 36 months under recommended storage conditions from date of manufacture or as per label specifications
  • Storage: Store between 2°C to 8°C for Pre-Filled Syringes/Lyophilized (Do not freeze). Does not require cold-chain logistics. Protect from moisture and direct sunlight. The solution should be used strictly as per label guidelines.

Regulatory Status & Supply Information:

  • Regulatory Status: WHO-GMP Complaint Manufacturing. COA, MSDS, Stability Data, Manufacturing Batch Record, Dossier Support (on request). Further certifications available on request
  • Exports Ready Dossiers: COA, COPP, Dossier Available (CTD/eCTD formats). Complies with USP/EP/BP Standards
  • Stability: Compliant
  • MOQ: Negotiable. Based on market & registration status
  • Export Options: Available for private label, institutional supply, or branded export

Who Should Source This Product?

  • Hospitals, ICUs, cardiac centers, and oncology care units
  • Government tenders and public health agencies
  • Distributors of cold-chain anticoagulants and emergency injectables
  • NGOs and humanitarian organizations managing stroke, surgery, and cancer care
  • Importers in LATAM, Africa, CIS & Southeast Asia focusing on life-saving critical care injectables
  • Pharmaceutical procurement bodies seeking reliable, WHO-GMP or EU-GMP certified LMWH injectables

Why Source from PHARMET?

  • Single-window sourcing for diverse pharma needs
  • Export-ready documentation & regulatory support
  • Adaptable documentation support for effective registration support
  • Trusted consortium network, simplifying India’s complex pharma supply chain
  • Multiple approved manufacturers for best fit in import country
  • Network of audited, compliant manufacturers across India
  • Customizable & Flexible branding, packaging & formulation flexibility
  • End to End Logistics support flexibility & support
  • Deep expertise in exporting specialty injectables & all products

CONTACT DETAILS:

Anticoagulant

Related items